casein-kinase-ii and Status-Epilepticus

Temporal lobe epilepsy (TLE) is the most common epileptic syndrome in adults and often presents with seizures that prove intractable with currently available anticonvulsants. Thus, there is still a need for new anti-seizure drugs in this condition. Recently, we found that the casein kinase 2 inhibitor 4,5,6,7-tetrabromotriazole (TBB) prevented the emergence of spontaneous epileptic discharges in an acute in vitro epilepsy model. This prompted us to study the anti-seizure effects of TBB in the pilocarpine model of chronic epilepsy in vivo. To this end, we performed long-term video-EEG monitoring lasting 78-167 days of nine chronically epileptic rats and obtained a baseline seizure rate of 3.3 ± 1.3 per day (baseline of 27-80 days). We found a significant age effect with more pronounced seizure rates in older animals as compared to younger ones. However, the seizure rate increased to 6.3 ± 2.2 per day during the oral TBB administration (treatment period of 21-50 days), and following discontinuation of TBB, this rate remained stable with 5.2 ± 1.4 seizures per day (follow-up of 30-55 days). After completing the video-EEG during the follow-up the hippocampal tissue was prepared and studied for the expression of the Ca

Topics: Administration, Oral; Animals; Anticonvulsants; CA1 Region, Hippocampal; Casein Kinase II; Disease Models, Animal; Electric Stimulation; Electroencephalography; Hydrocarbons, Brominated; Male; Maze Learning; Muscarinic Agonists; Neurotransmitter Agents; Pilocarpine; Potassium Channels, Calcium-Activated; Rats; Rats, Wistar; Status Epilepticus; Triazoles; Up-Regulation; Video Recording